

DOES VALUATION OF INNOVATION IN APPRAISAL OF NEW TECHNOLOGIES PROVIDE APPROPRIATE INCENTIVES FOR MANUFACTURERS AND ACCESS FOR PATIENTS?

Mark Sculpher, PhD

*Professor of Health Economics
Centre for Health Economics
University of York, UK*

Workshop W6, ISPOR 20th Annual European Congress, Glasgow


THE UNIVERSITY *of York*



A model of HTA emerging internationally?



Cost-effectiveness and price



Claxton et al. *British Medical Journal* 2008;336:251-4.

Does this provide an appropriate incentive to manufacturers?

- Is health measured appropriately?
- Are there benefits other than health that should be reflected?
- Should future health gains from major innovation be counted?
- Should each jurisdiction pay a 'fair share' to incentivize innovation?

Speakers



Ross Maclean

Senior Vice President, Head of Medical,
at Precision Health Economics, USA

Speakers



Karl Claxton

Professor of Economics
University of York, UK

Speakers



Jens Grueger

Head of Global Pricing & Market Access
Hoffmann-La Roche
Switzerland